RT Journal Article
T1 Cellular and Molecular Mechanisms Underlying Glioblastoma and Zebrafish Models for the Discovery of New Treatments
A1 Reimunde Figueira, Pedro Marcos
A1 Pensado López, Alba
A1 Carreira Crende, Martín
A1 Lombao Iglesias, Vanesa
A1 Sánchez Piñón, Laura
A1 Torrecilla Parra, Marta
A1 Ramírez, Cristina M.
A1 Anfray, Clément
A1 Torres Andón, Fernando
K1 Glioblastoma
K1 Cancer
K1 Tumor microenvironment
K1 Glioma-associated microglia/macrophages
K1 Genetics
K1 Metabolism
K1 miRNA
K1 Zebrafish
K1 Drug discovery
AB Glioblastoma (GBM) is the most common of all brain malignant tumors; it displays a median survival of 14.6 months with current complete standard treatment. High heterogeneity, aggressive and invasive behavior, the impossibility of completing tumor resection, limitations for drug administration and therapeutic resistance to current treatments are the main problems presented by this pathology. In recent years, our knowledge of GBM physiopathology has advanced significantly, generating relevant information on the cellular heterogeneity of GBM tumors, including cancer and immune cells such as macrophages/microglia, genetic, epigenetic and metabolic alterations, comprising changes in miRNA expression. In this scenario, the zebrafish has arisen as a promising animal model to progress further due to its unique characteristics, such as transparency, ease of genetic manipulation, ethical and economic advantages and also conservation of the major brain regions and blood–brain–barrier (BBB) which are similar to a human structure. A few papers described in this review, using genetic and xenotransplantation zebrafish models have been used to study GBM as well as to test the anti-tumoral efficacy of new drugs, their ability to interact with target cells, modulate the tumor microenvironment, cross the BBB and/or their toxicity. Prospective studies following these lines of research may lead to a better diagnosis, prognosis and treatment of patients with GBM
PB MDPI
YR 2021
FD 2021
LK http://hdl.handle.net/10347/24730
UL http://hdl.handle.net/10347/24730
LA eng
NO Cancers 2021, 13(5), 1087; https://doi.org/10.3390/cancers13051087
NO F.T.A. has been supported by the AECC (“Asociación Española Contra el Cáncer”, Spain). We would also like to thank the following: the Talento Program from Madrid Government, Spain (2017-T1/BMD-5333); Convocatoria 2018 de proyectos de I+D+i «RETOS INVESTIGACIÓN» (RTI2018-095061-B-I00) (to C.M.R.); “Convocatoria de ayudas para la contratación de ayudantes de investigación” (PEJ-2018-AI/BMD-9724) (to M.T.-P.); the Xunta de Galicia Pre-doctoral Fellowship (ED481A-2018/095) (to A.P.L.)
DS Minerva
RD 30 abr 2026